Review

cGAS-Stimulator of Interferon Genes Signaling in Central Nervous System Disorders

Fengjuan Li1, Ningqun Wang2, Yangmin Zheng2, Yumin Luo2,* Yongbo Zhang1,*

1Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
2Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing 100053, China

[Received January 5, 2021; Revised March 4, 2021; Accepted March 4, 2021]

ABSTRACT: Cytosolic nucleic acid sensors contribute to the initiation of innate immune responses by playing a critical role in the detection of pathogens and endogenous nucleic acids. The cytosolic DNA sensor cyclic-GMP-AMP synthase (cGAS) and its downstream effector, stimulator of interferon genes (STING), mediate innate immune signaling by promoting the release of type I interferons (IFNs) and other inflammatory cytokines. These biomolecules are suggested to play critical roles in host defense, senescence, and tumor immunity. Recent studies have demonstrated that cGAS-STING signaling is strongly implicated in the pathogenesis of central nervous system (CNS) diseases which are underscored by neuroinflammatory-driven disease progression. Understanding and regulating the interactions between cGAS-STING signaling and the nervous system may thus provide an effective approach to prevent or delay late-onset CNS disorders. Here, we present a review of recent advances in the literature on cGAS-STING signaling and provide a comprehensive overview of the modulatory patterns of the cGAS-STING pathway in CNS disorders.

Key words: cGAS, STING, cGAS-STING, CNS disorders

The innate immune system is the first line of defense against microbial infections and is essential for the activation of adaptive immunity. Innate immune recognition is mediated by a vast array of germline-encoded innate immune receptors, often referred to as pattern recognition receptors (PRRs) [1]. PRRs play an essential role in the sensing of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). For example, toll-like receptors (TLRs) recognize a variety of PAMPs and DAMPs which initiate the process of inflammation via the activation of nuclear factor (NF)-κB and the synthesis and release of cytokines and interferons (IFNs) [2]. Inflammasomes are a distinct class of intracellularly expressed PRRs that recognize nucleic acids and mediate pro-inflammatory responses [3]. In addition to these PRRs, the cyclic-GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) axis has been identified as a major nucleic acid recognition pathway. cGAS typically resides as an inactive protein in the cell and is activated upon binding to aberrant DNA. Activated cGAS then synthesizes 2′,3′-cGAMP, which acts as a secondary messenger that activates STING [4,5]. Activated STING translocates to the Golgi and activates tank-binding kinase 1 (TBK1), resulting in phosphorylation of TBK1. TBK1 phosphorylates type I interferon regulatory factor 3 (IRF3) [6], which then dimerizes and translocates into the nucleus, where it functions concomitantly with NF-κB, a transcription factor activated by STING. This induces the expression of type I IFNs and inflammatory cytokines, leading to antiviral immune responses [7, 8] (Fig.1).
Figure 1. Activation of cGAS-STING signaling pathway. cGAS is activated by sensing cytosolic DNA either from pathogenic DNA or self-DNA. Activated cGAS utilizes ATP and GTP to produce the second messenger cGAMP. cGAMP binds to the ER adaptor STING, which can also be activated by CDNs derived from bacteria. Activated STING translocates from the ER to Golgi compartments and recruits TBK1, which further recruits IRF3 for phosphorylation and dimerization. The phosphorylated IRF3 dimer then enters the nucleus and functions in concert with NF-κB to induce the expression of type I IFNs and inflammatory cytokines.

Mounting evidence has demonstrated that the physiological and pathological relevance of cGAS and STING extends far beyond “traditional” antiviral immunity [8]. Increased cytosolic DNA levels due to factors such as mitotic stress in cancers, cellular senescence, or autoimmune disorders may lead to cGAS-STING activation and aggravation of pathological progression [9-11]. Research on the role of the cGAS-STING pathway in CNS disorders has grown in recent years. Constitutive and systemic activation of cGAS-STING results in chronic neuroinflammation and neurodegeneration. There has yet to be a comprehensive review of this topic. In this review, we present recent advances in the literature on cGAS-STING signaling, focusing on the contribution of the cGAS-STING axis to CNS disorders.

Recognition of dsDNA by cGAS and formation of cGAMP

cGAS mediates DNA-sensing via direct binding, which triggers conformational changes that induce enzymatic activity [12]. cGAS dimerization increases with DNA binding depending on the length of the bound DNA [13]. Double-stranded DNA (dsDNA) equal to or more than 36bp in length is optimal for recognition by cGAS [4]. cGAS is activated by pathogenic DNA, such as viral and bacterial DNA, as well as self-DNA, such as nuclear DNA derived from dead cells or tumor cells that have damaged DNA repair and mitochondrial DNA (mtDNA) resulting from mitochondrial oxidant damage. Studies have demonstrated that BAX and BAK can permeabilize the outer mitochondrial membrane. In the context of caspase inhibition, these pores grow substantially, allowing inner membrane herniation and extrusion of mtDNA [14, 15].
In the absence of apoptotic caspase, mtDNA activates cGAS in a promiscuous manner, which leads to elevated IFN-β [16, 17]. cGAS was originally assumed to be primarily cytosolic, thereby avoiding persistent activation by self-DNA in the nucleus [18, 19]. The DNA replication and repair factors, RPA and Rad51, constitute an intrinsic cellular mechanism that protects the cytosol from self-DNA [20]. However, this idea has been challenged by several recent studies demonstrating that cGAS is also localized in the nucleus and is tightly tethered to chromatin [21,22]. cGAS has been reported to interact with histone 2A-histone 2B and is tightly anchored to the acidic patch [23-27]. Volkmann et al. demonstrated that the majority of cGAS proteins resided in the nucleus, and the authors proposed a model whereby cGAS must be “desequestered” prior to its full activation [21]. Another study demonstrated that cytosolic cGAS was largely localized to the plasma membrane, which enabled more rapid and efficient detection of viral DNA that entered the cell via endocytosis [28]. Nevertheless, the mechanisms by which cGAS avoids inappropriate sensing of self-DNA remain unclear.

Active cGAS converts GTP and ATP into cGAMP, which contains one 2′,5′- phosphodiester linkage and a canonical 3′,5′-linkage (c[G2′,5′pA(3′,5′)p]) [5, 20, 29]. cGAMP activates STING, which triggers type I IFNs responses. Other cyclic dinucleotides (CDNs), including cyclic di-GMP and cyclic di-AMP, are secreted during intracellular bacterial infections and directly activate STING [30, 31]. STING is also known to bind dsDNA directly [32], although the physiological relevance of this remains to be clarified. cGAMP can be transferred between cells via gap junctions, which may stimulate the activation of the IFN pathway in uninfected neighboring cells to promote resistance to infection [33]. cGAMP packaged into viral particles may also be transferred into newly infected cells [34]. SLC19A1, a folate-organic phosphate antipporter, has been implicated in the transport of extracellular cGAMP into the cytosol [35, 36]. Moreover, LRRC8A:C/E transports cGAMP into bystander cells, a process mediated by STING activation [37, 38]. cGAMP is degraded by a specific mammalian phosphodiesterase, ENPP1, which controls cGAMP uptake by cells [39]. In addition to triggering STING, extracellular cGAMP can directly bind to cGAS and induce its activation [40].

Activation of STING and downstream signals

STING is retained in the endoplasmic reticulum (ER) by interacting with the Ca2+ sensor, stromal interaction molecule 1 (STIM1) [41]. The cytosolic ligand-binding domain (LBD) of STING is the most functional unit capable of integrating with cGAMP. Upon interaction, closure of the ligand binding pocket in the LBD occurs, leading to the activation of STING [42]. Following stimulation, STING traffics to the Golgi and ER-Golgi intermediate compartments (ERGIC), resulting in recruitment of TBK1 and activation of the STING signalingosome [43]. STING ER exit protein (STEEP/CxORF56) interacts with STING and promotes trafficking from the ER [44]. This process is mediated by the stimulation of phosphatidylinositol-3-phosphate (PtdIns(3)P) production and ER membrane curvature formation, which induce coat protein complex II (COP-II)-mediated ER-to-Golgi trafficking of STING [44]. SNX8 recruits VPS34 to STING, which is required for trafficking of STING [45]. Various factors, including iRhom2, SCAP, INSIG1, and TMED2 facilitate ER-to-Golgi trafficking [46-49]. Blocking ER-to-Golgi trafficking with brefeldin A and Shigella effector protein IpaJ abolishes phosphorylation of IRF3 and induction of type I IFNs [43, 50, 51]. Further, knockdown of the small GTPase Sar1 regulates COP-II-mediated ER-to-Golgi trafficking and inhibits the translocation of STING from the ER and phosphorylation of IRF3 [52]. Mutations in COPA, which encodes the α-subunit of the COPI complex, result in chronic elevation of type I IFNs [53]. COPI promotes retrograde Golgi-ER transport, and mutant COPA is associated with an accumulation of STING in the Golgi [54]. These results imply that translocation of STING is associated with its activation. However, the molecular hierarchy of this process and the coordination with COPII trafficking are not fully understood. In the Golgi, STING is palmitoylated at two cysteine residues (Cys88/91), which is necessary for STING activation [55, 56]. The STING signalingosome produces a scaffold for the phosphorylation of IRF3 and NF-κB, which further translocate into the nucleus and promote the transcription of genes encoding type I IFNs and other cytokines such as tumor necrosis factor (TNF), interleukin (IL)-1β, and IL-6, which stimulate the immune response [57].

Regulation of cGAS-STING pathway

Tight regulation of the cGAS-STING pathway is necessary to maintain innate immune homeostasis. Post-translational modifications (PTMs) such as phosphorylation, ubiquitination, and glutamylation play important roles in the regulation of the cGAS-STING pathway. Here, we canvass factors in the literature that may regulate cGAS (Table 1) and STING (Table 2). cGAS and STING are also targeted by various viral proteins, but these lie outside the scope of this review and will not be discussed further.
Table 1. The regulation factors of cGAS.

| Mechanisms | Factors | Functions | Effects | Ref. |
|------------|---------|-----------|---------|------|
| Acetylation | KAT5    | Acetylation at multiple lysine residues in its N-terminal domain | Promotes its DNA binding ability | [58] |
| Ubiquitination | RNF185 | K27-linked ubiquitination at K137, K384 | Enhances production of IFN | [59] |
| TRIM56     | Monoubiquitination at K33 | Increases its DNA binding activity and cGAMP production | [60] |
| TRIM14     | Recruiting USP14 to cleave K48-linked ubiquitination at K414 | Inhibits its degradation | [61] |
| Phosphorylation | AKT | Phosphorylation at S305 (human) or S291 (mouse) | Inhibits its catalytic activity | [62] |
| Sumoylation | TRIM38 | Sumoylation at K217 or K464 | Promotes its stabilization | [63] |
| SENP2      | Desumoylation at K217 or K464 | Induces its degradation | [63] |
| SENP7      | Desumoylation at K217 or K464 | Activates sumoylated cGAS | [64] |
| Glutamylation | TTL6/1 | Polyglutamylation at E272/monglutamylation at E302 | Inhibits its DNA binding capacity | [65] |
| TTL4       | Deglutamylation at E272/E302 | Releases the inhibitory effects of glutamylation | [65] |
| CCPR6/8    | Deglutamylation at E272/E302 | Efficient activation of cGAS | [66] |
| Other mechanisms | G3BP1 | Promoting the formation of large cGAS complexes | Efficient innate immune response | [67] |
|            | OASL    | Bounding to cGAS | Inhibits its enzyme activity | [68] |
|            | ZCCHC3  | Enhancing the binding of cGAS to dsDNA | | |

### cGAS-STING signaling in CNS disorders

Neuroinflammation is a CNS defense mechanism induced by various pathological insults such as ischemia, trauma, infection, and toxins [91]. This inflammatory response protects the brain by removing or inhibiting pathogens and promoting tissue repair. However, prolonged neuroinflammation elicits secondary injury, leading to progressive neurodegeneration [92, 93]. The specialized immune system of the CNS detects foreign pathogens and tissue damage, initiates immunological interventions at the local level, and recruits help from the periphery to aid in efficient clearance of pathogens and/or debris [94]. Neuroinflammation leads to infiltration of peripheral immune cells, especially neutrophils and monocytes/macrophages, via the disrupted blood-brain barrier (BBB). Neuroinflammatory responses are mediated by pro-inflammatory cytokines, including IL-1β, IL-6, and TNF; chemokines such as CCL1, CCL5, CXCL1; small-molecule messengers, including nitric oxide (NO) and prostaglandins; and reactive oxygen species (ROS) produced by innate immune cells in the CNS [95]. Microglia are the principal innate immune cells in the brain and the first responders to pathological insults [96]. Indeed, much of the innate immune capacity of the CNS is mediated by microglia [97]. Activated microglia rapidly alter their transcriptional profile, migrate towards sites of injury or infection, and produce inflammatory cytokines and chemokines [94] (Fig.2).

Activation of the innate immune system involves the induction of the type I IFN-stimulated genes (ISGs) by the mechanisms described earlier. STING is predominantly expressed in microglia, although neurons and astrocytes also produce IFN [95]. Many neuroinflammatory diseases, such as ischemic injury, subarachnoid hemorrhage, traumatic brain injury (TBI), Alzheimer’s disease (AD), and Parkinson’s disease (PD) are characterized by activation of the cGAS-STING pathway and expression of type I IFNs and inflammatory cytokines which underscore pathological progression. In the following text, we discuss the role of cGAS-STING signaling in CNS disorders (Fig.3).

### Ischemic stroke and subarachnoid hemorrhage (SAH)

The cGAS-STING pathway is activated during ischemic injury, which is a debilitating neurological disorder that results in elevated neuroinflammation. Middle cerebral artery occlusion (MCAO), a murine model of ischemic stroke, increases the release of dsDNA into the cytosol and initiates inflammatory responses by activating cGAS [98]. Treatment with A151, an inhibitor of cGAS, reduces the expression of cGAS and neuroinflammatory responses. Moreover, A151 administration significantly reduces infarct volume and ameliorates neurodegeneration in MCAO mice [98]. Liao et al. demonstrated that the microglial cGAS-STING pathway was activated following transient MCAO (tMCAO), which promoted the formation of a pro-inflammatory microenvironment. In addition, they demonstrated that histone deacetylase
(HDAC)3 regulated the acetylation and nuclear localization of p65, which promoted the expression of cGAS and potentiated the activation of the cGAS-STING pathway. Deletion of cGAS or HDAC3 in microglia attenuates neuroinflammation and brain injury in tMCAO mice, highlighting a novel therapeutic avenue for the treatment of ischemic stroke [99]. Ischemic stroke is characterized by lack of oxygen and glucose in local brain tissue [100]. McDonough et al. reported that the expression of ISGs was upregulated within microglia exposed to ischemia/reperfusion (I/R) in both in vitro and in vivo experimental paradigms [101]. Deletion of either IFN-alpha receptor 1 (IFNAR1) or IRF3 exerts protective effects on tMCAO [102, 103]. The STING pathway is also relevant to neovascularization and vascular remodeling. STING knockdown and IFN receptor-neutralizing antibody treatment reduce BBB breakdown and increase vascular plasticity [104]. Collectively, these studies indicate that activation of the endogenous cGAS-STING cascade may be detrimental to the outcomes of ischemic stroke.

Neuroinflammation has recently been implicated in secondary injury following SAH [105]. Preclinical studies have indicated that suppressing neuroinflammation confers increased neurological outcomes after SAH [106, 107]. STING expression increases significantly after SAH, predominantly in microglia. Administration of C-176, a small-molecule inhibitor of STING, confers robust anti-inflammatory effects, alleviates neuroinflammation, and ameliorates short-term and persistent neurological dysfunction after SAH. Further, administration of the STING agonist CMA promotes microglial activation, aggravates neuroinflammation, exacerbates neuronal injury, and increases neurological impairments [108]. These findings suggest that STING is an important regulator of SAH-induced neuroinflammation.

Figure 2. The effect of neuroinflammation in the disruption of CNS homeostasis. Neuroinflammation is accompanied by increased blood-brain barrier (BBB) permeability. Peripheral immune cells, including neutrophils and monocytes/macrophages, are recruited to the lesion site via the disrupted BBB. Microglia are the principal innate immune cells in the brain and produce a range of cytokines at the early stage of neuroinflammation that mediate clearance of pathogens and debris and promote injury repair. In contrast, prolonged neuroinflammation elicits secondary injury, which affects nearby neuronal and glial cells and leads to neurodegeneration.
### Table 2. The regulation factors of STING.

| Mechanisms | Factors | Functions | Effects | Ref. |
|------------|---------|-----------|---------|------|
| Ubiquitination | TRIM56 | K63-linked polyubiquitination at K150 | Induces STING dimerization | [69] |
| | TRIM32 | K63-linked polyubiquitination at K20, K224, K236 | Promotes the interaction with TBK1 | [70] |
| | MUL1 | K63-linked ubiquitination at K224 | Enhances IRF3-dependent signaling | [71] |
| | AMFR | K27-linked polyubiquitination at K137, K150, K224, and K236 | Facilitates TBK1 recruitment and activation | [48] |
| | TRIM30α | K48-linked ubiquitination at K275 | Promotes the degradation of STING | [72] |
| | RNFL5 | K48-linked polyubiquitination at K150 | Mediates its degradation | [73] |
| | TRIM29 | K48-linked polyubiquitination at K370 | Mediates its degradation | [74] |
| | RNFL26 | K11-linked polyubiquitination at K150 | Protects STING from degradation | [75] |
| | MYSM1 | Cleaving K63-linked ubiquitination | Represses the production of IFN | [76] |
| | USP49 | Deconjugating K63-linked ubiquitination | Terminates innate antiviral responses | [77] |
| | USP20 | Deconjugating K48-linked ubiquitination | Facilitates STING-mediated signaling | [78] |
| | CYLD | Deconjugating K48-linked ubiquitination | Boosts the innate antiviral response | [79] |
| | USP21 | Hydrolyzing K27/63-linked polyubiquitin chain | Reduces the production of IFN | [80] |
| | USP13 | Deconjugating K27-linked polyubiquitination | Negatively regulates cellular antiviral responses | [81] |
| | EIF3S5 | Deconjugating K48-linked polyubiquitination | Stabilizes STING protein | [46] |
| SUMOylation | TRIM38 | Sumoylating at K337 (murine) or K338 (human) | Promotes its stability and activation | [63] |
| Phosphorylation | SENP2 | Desumoylating STING | Induces its degradation | [63] |
| | ULK1 | Phosphorylating at S366 | Suppresses IRF3 activation | [51] |
| | PTPN1/2 | Dephosphorylating at Y245 | Leads to its degradation | [82] |
| | PPM1A | Dephosphorylating at S358 | Prevents its aggregation | [83] |
| | S6K1 | Interacting with phosphorylated STING and TBK1 | Induces IRF3 activation | [84] |
| Other mechanisms | TOLLIP | Directing interaction with STING | Prevents STING degradation at the resting state | [85] |
| | NLRC3 | Breaking the association of STING with TBK1 | Negatively regulates innate immune signaling | [86] |
| | NLRX1 | Blocking the assembly of the STING–TBK1 complex | Inhibits IFN response and facilitates viral spread | [87,88] |
| | ZDHHC1 | Mediating STING aggregation and recruitment of TBK1 and IRF3 | Positively regulates innate immune response | [89] |
| | TMEM203 | Interacting with STING | Activates TBK1 and IRF3 | [90] |
| | TMED2 | Reinforcing STING dimerization | Potentiates IFN responses | [49] |
Figure 3. cGAS-STING signaling pathway in CNS disorders. cGAS-STING signaling pathway is involved in neuroinflammation in various CNS disorders such as ischemic stroke, SAH, TBI, AD, and PD. These markers are expressed predominantly in microglia and play different roles depending on the type of disease. This axis acts as a contributing factor to the production of type I IFNs and inflammatory cytokines and promotes microglial phagocytosis. It may also lead to secondary injury and aggravate the pathological progression of CNS disorders.

**Traumatic brain injury (TBI)**

TBI is a widespread public health concern that results from excessive contact in sports, blast injuries in war, or occupational hazards [109]. Neuroinflammation plays an integral role in the pathophysiology of TBI by promoting the clearance of debris and regeneration, as well as mediating neuronal death and progressive neurodegeneration [110]. Microglial and peripheral inflammatory cells respond to TBI and provide neuroprotection or participate in maladaptive secondary injury reactions [111]. Type I IFNs are upregulated in postmortem human TBI brains and activate proinflammatory microglia in murine models of TBI [112]. A recent study documented that TBI resulted in acute (within 72 h post-injury) upregulation of cGAS and STING in a mouse model of TBI [113]. Type I IFNs, neuroinflammatory genes, and proinflammatory mediators in the cortex and hippocampus are upregulated following TBI. Knock-down of IFN-β results in decreased levels of these inflammatory markers, and an attenuation of behavioral deficits [113]. Abdullah et al. reported that STING expression was elevated in postmortem human TBI brains; this finding has been confirmed in murine models of TBI. STING deletion suppresses the expression of type I IFNs, accompanied by a reduction in lesion volume [114]. Sen et al. reported that STING signaling was activated by neuronal ER stress [115]. Phosphorylation of protein kinase R-like endoplasmic reticulum kinase (PERK) initiates ER stress after TBI [116]. Blockade of PERK abrogates the STING signaling cascade, thereby reducing neuroinflammation and cognitive impairments [115]. Collectively, these findings highlight a novel targetable signaling axis following TBI.
Alzheimer’s disease and ataxia-telangiectasia

Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterized by progressive memory loss and behavioral changes [117]. The essential roles of inflammation in AD pathophysiology is increasingly being recognized [118]. Increased levels of inflammatory markers in patients with AD and the identification of AD risk genes suggest that neuroinflammation plays a prominent role in AD pathogenesis [91, 119]. Indeed, the contribution of neuroinflammation to AD pathogenesis is commensurate (or even exceeds) that of senile plaques and neurofibrillary tangles [120]. Microglial activation was observed at the pre-plaque stage in a transgenic rat model of AD and in individuals with mild cognitive impairment (MCI) without amyloid tracer uptake in a neuroimaging study [121, 122]. Studies have also demonstrated the influence of neuroinflammation at the symptomatic stage of AD [123, 124]. Emerging evidence suggests that the STING pathway is hyperactivated with aging due to internal factors such as chromatin and mtDNA fragments in the cytosol [125, 126]. A rare mutation of the triggering receptor expressed on myeloid cells 2 (TREM2) increases the risk of AD to a similar extent as that for apolipoprotein E (ApoE) e4 [127, 128]. TREM2 is highly expressed by microglia and promotes Aβ clearance [129]. However, TREM2 mutations aggravate the accumulation of Aβ and neuroinflammation in the brain. Xu et al. reported that cGAMP induced TREM2 expression, which decreased Aβ deposition and ameliorated cognitive impairments [130], highlighting the therapeutic potential of targeting cGAMP to treat AD.

Ataxia-telangiectasia (A-T) is a progressive neurodegenerative disease caused by mutations in the ataxia telangiectasia mutated (ATM) gene. ATM plays a major role in sensing and coordinating the repair of DNA double-strand breaks (DSBs). ATM deficiency leads to a breakdown of DNA repair mechanisms and an accumulation of cytoplasmic fragments of nuclear DNA, resulting in activation of the STING signaling cascade and overproduction of cytokines [131]. Inhibition of STING blocks the overproduction of neurotoxic cytokines. ATM deficiency induces STING-mediated IFN production, which promotes anti-microbial immunity [132]. Thus, inhibition of ATM may be a promising approach to boost cellular innate immunity and enhance immune checkpoint blockade therapy. A recent study reported that ATM inhibition potently activated the cGAS-STING pathway and further enhanced immunotherapy by downregulating mitochondrial transcription factor A (TFAM), which resulted in mtDNA leakage into the cytoplasm [133]. Accumulation of cytosolic DNA has been observed in the hippocampus, cerebellum, and spinal cord in rat models of A-T; these events contribute to microglial activation and increased production of IFN-β and IL-1β [134, 135]. Betamethasone treatment reduces neuroinflammatory responses and motor neuron loss, and extends the lifespan of ATM knockout rats [134]. In sum, these studies indicate that cGAS-STING signaling and neuroinflammation play an essential role in the pathogenesis of AD and A-T.

Parkinson’s disease (PD), Huntington disease (HD), and amyotrophic lateral sclerosis (ALS)

PD is the second most common age-related neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra, involving both motor and non-motor symptoms [136]. Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a major cause of PD. LRRK2 is involved in immune system responses and mitochondrial function. Loss of LRRK2 in macrophages induces elevated IFN and ISGs, which are driven by mtDNA leakage into the cytosol and chronic cGAS engagement [137]. Pink1 and Parkin work in concert in mitophagy, thereby removing damaged mitochondria [138]. In a mouse model of Parkin knockout mutants combined with a mtDNA mutator strain, selective degeneration of nigral dopaminergic neurons, increased mitochondrial dysfunction, and a decline in motor ability were noted [139]. Supporting these observations, mice lacking Parkin and Pink1 in mutator combination exhibit a strong inflammatory phenotype that results from mtDNA mutational stress, which activates the cGAS-STING pathway. In addition, genetic inactivation of STING prevents exercise and cytokine production, resulting in rescue of neurodegeneration and locomotor deficits [140]. These findings strongly implicate the induction of STING in the pathogenesis of PD. In contrast, a study reported that loss of STING was insufficient to suppress behavioral deficits or mitochondrial disruption in Drosophila Pink1/Parkin or mtDNA mutator models [141]. The reasons for these discrepant results are unclear. One possibility is that aberrant innate immune activation is not mediated by the presence of cytosolic DNA or by activation of the STING pathway. A recent clinical study reported elevated levels of IL-6 and mtDNA in carriers of Parkin/Pink1 mutations, suggesting that inflammation plays a role in PD pathogenesis [142].

HD is an autosomal dominant inherited neurodegenerative disorder caused by mutations in the Huntingtin gene. HD is characterized by impairments in motor, psychiatric, and cognitive functions [143]. Inflammatory responses are implicated in the pathogenesis of HD [144, 145]. Ribosome profiling revealed that cGAS mRNA has high ribosome occupancy...
in HD striatal cells derived from mouse embryos. cGAS activity is enhanced, and the expression of inflammatory genes and autophagy proteins is increased. Depletion of cGAS decreases inflammatory and autophagy responses in HD striatal cells, indicating that cGAS promotes inflammatory responses in HD and may be a therapeutic target for HD [146].

ALS is a devastating disease that involves loss of motor neurons, leading to progressive impairments in motor function [147]. In a German ALS population study, higher education and living in a rural environment was associated with a higher risk of developing ALS [148]. In addition, emotional ability at disease onset is associated with faster disease progression in ALS [149]. TAR DNA-binding protein of 43 kDa (TDP-43) is an RNA/DNA-binding protein that regulates mRNA splicing, stability, and translation in the nucleus. Cytoplasmic accumulation of TDP-43 is observed in neurons of almost all patients with ALS [147]. TDP-43-mediated neurodegeneration in ALS is associated with increased proinflammatory cytokine production related to elevated NF-κB and type I IFNs signature [150, 151]; these effects are driven by the cGAS-STING pathway [152]. TDP-43 invades mitochondria and releases mtDNA, which is detected by cGAS and leads to further activation of STING. Further, elevated levels of cGAMP, the specific cGAS signaling metabolite, have been observed in spinal cord samples of ALS patients [152].

Expansions of a GGGGCC repeat in the C9orf72 gene are the most commonly identified genetic cause of ALS/frontotemporal dementia (C9-ALS/FTD) [153]. Marked expression of type I IFNs mediated by STING in dendritic cells isolated from C9orf72-deficient mice have been observed, and blocking STING suppresses the type I IFNs response. Moreover, an elevated type I IFNs signature has been observed in blood-derived macrophages and brain tissue of patients with C9-ALS/FTD, and this elevated signature can be suppressed with administration of a STING inhibitor [154]. Collectively, these findings suggest that targeting the cGAS-STING pathway is a viable therapeutic strategy to alleviate the damage caused by ALS.

**Multiple sclerosis and Aicardi-Goutières syndrome**

Multiple sclerosis (MS) is an inflammatory and autoimmune neurological disorder characterized by demyelination [155]. Immunomodulatory therapies such as IFN and rituximab prevent or delay the progression of MS [156]. IFN-β is thought to mediate beneficial effects by targeting innate and adaptive immune cells. Microglia are abundant in MS lesions. Microglial activation is often remote from lesions and may represent the earliest stage of lesion development [157].

Mathur and colleagues reported that ganciclovir (GCV) treatment resulted in an upregulation of several antiviral proteins in cultured microglia, including CXCL10 and IFN-β, at both the mRNA and protein levels [158]. In experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, STING is exclusively expressed in microglia, and GCV induces a type I IFNs response dependent on activated STING. Notably, this response is necessary for GCV to inhibit inflammation in cultured myeloid cells and in EAE. Inhibition of STING pathway mediators, such as STING, IRF3, and TBK1, results in reduced activity of GCV. GCV may mimic CDNs and activate the STING pathway [158]. Similarly, Lemos et al. demonstrated that administration of DNA nanoparticles (DNPs) and CDNs significantly delayed EAE onset and reduced disease severity. DNPs and CDN activates the STING pathway and attenuate infiltration of effector T cells into the CNS, highlighting the beneficial effects of STING in vivo [159]. Further, STING/IFN-β is downregulated in relapse-remitting MS (RRMS) patients [160]. These observations have shed insight into the role of STING as a potent immune regulator in MS.

Aicardi-Goutières syndrome (AGS) is a rare lupus-like autoimmune disease characterized by excessive production of type I IFNs. AGS is driven by mutations in genes involved in nucleic acid transactions, including TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1 [161]. TREX1 (DNase III) is an exonuclease that degrades DNA in the cytoplasm. Loss of Trex1 in dendritic cells is sufficient to cause IFN release and autoimmunity [162]. Genetic ablation of cGAS alleviates autoimmune phenotypes, suppresses the expression of ISGs, and decreases T-cell activation, suggesting that cGAS activation induced by accumulated DNA is involved in AGS [9].

Vincent et al. developed a small-molecule inhibitor of cGAS, RU.521, that reduced constitutive expression of IFN in macrophages in a mouse model of AGS [163]. STING and TBK1 have also been implicated in the inflammatory response of AGS [164, 165]. Rnase H2-deficient mice exhibit increased expression of ISGs dependent on the cGAS-STING signaling pathway, and ablation of STING partially rescues perinatal lethality [166].

**Encephalitis**

Acute viral encephalitis is a devastating disease that can cause irreversible damage and even death [168]. Herpes
simplex virus type 1 (HSV-1) is the primary cause of viral encephalitis that accounts for 50–75% of all viral cases [169]. Early production of IFN is critical for controlling the spread of CNS viral infections. Microglia are the main producers of type I IFNs following HSV-1 infection, a response that is dependent on the cGAS-STING signaling axis. Mice defective in cGAS or STING are highly susceptible to HSV-1 infection [170]. HSV-infected microglia confer STING-dependent antiviral activity in neurons and prime type I IFNs production in astrocytes via the TLR3 pathway [170]. HSV-1 infected microglia undergo apoptosis at high viral levels and induce IFN-mediated responses at low viral doses, effects that are dependent on cGAS [171]. Bodda et al, reported that a HSV1 mutant lacking deubiquitinase (DUB) activity of the VP1-2 protein induced elevated IFN expression in microglia and STING phosphorylation [172]. VP1-2 is directly associated with STING, leading to its deubiquitination, blocking IFN expression, and promoting brain infection. DUB activity of HSV1 VP1-2 is a major viral immune-evasion mechanism in the brain [172]. Further, HSV-1 UL37 tegument protein impairs the catalytic ability of cGAS and disarms host defenses. Consistent with these findings, inactivating mutations in HSV-1 UL37 induce more robust cytokine responses, lower brain viral loads, and higher survival rates [173].

Japanese encephalitis virus (JEV), a flavivirus with single-stranded RNA, is recognized by RIG-I and acts in concert with STING to induce IFN-mediated responses. STING ablation inhibits inflammatory molecules and increases intracellular viral load. Conversely, overexpression of STING decreases intracellular viral load [174]. STING signaling is also involved in encephalitis caused by West Nile virus infections, and STING knockouts exhibit increased mortality, viral load, and aberrant T cell responses that are linked with CNS pathology in a murine model of infection [175].

Zika virus (ZIKV) is a member of the flavivirus genus of RNA viruses which can infect the fetal brain during pregnancy and result in significant brain abnormalities [176]. ZIKV predominantly infects neural stem cells and induces serious neurological complications during fetal development [177]. STING confers protection against ZIKV by inducing autophagy, while loss of autophagy leads to increased ZIKV infection and death [178]. Cao et al. reported that inhibition of autophagy limited vertical transmission of ZIKV and ameliorated adverse placental or fetal outcomes in a mouse model of pregnancy [179]. ZIKV attenuates STING signaling in primate cells via NS2B3 protease [180]. Lennemann and Coyne demonstrated that ZIKV NS2B3 protease cleaved FAM134B (an ER-localized reticulophagy receptor), suppressed the reticulophagy pathway, and promoted viral replication [181]. Nevertheless, it remains unclear whether autophagy suppresses ZIKV infections in the mammalian brain.

Conclusions

The cGAS-STING pathway is essential for modulation of the innate immune response. This signaling pathway is a double-edged sword in CNS disorders. It acts as a contributing factor by providing defense mechanisms via the regulation of type I IFNs production and spreading of immune signaling to adjacent cells. However, its overactivation may lead to secondary injury and aggravate the pathological progression of CNS disorders. These findings have spurred efforts to harness this natural defense-related pathway in the generation of brain disorders therapy.

In this review, we summarize the recent advances in cGAS-STING signaling, and its crucial role in the pathogenesis of CNS disorders. The activation of cGAS and STING may exert either positive or negative influences, depending on the context. Further research on this pathway will pave the way for deriving novel targets to halt disease progression or reverse symptoms at an early stage. For example, remaining questions include how the different regulators of the cGAS-STING pathway reciprocally interact and how the activities of these enzymes are regulated in a timely manner. To date, studies of the cGAS-STING pathway in CNS disorders have predominantly been conducted in preclinical settings, and further studies are necessary to explore the clinical relevance of this pathway.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant Nos 81671191, 81971222, and 82001390).

Conflicts of interest

The authors disclose no potential conflicts of interest.

References

[1] Medzhitov R, Janeway CJ (2000). Innate immunity. N Engl J Med, 343:338-344.
[2] Vijay K (2018). Toll-like receptors in immunity and inflammatory diseases: Past, present, and future. Int Immunopharmacol, 59:391-412.
[3] Paludan SR, Bowie AG (2013). Immune sensing of DNA. Immunity, 38:870-880.
[4] Gao P, Ascano M, Wu Y, Barchet W, Gaffney BL, Zillinger T, et al. (2013). Cyclic [G(2',5')pA(3',5')p] is the metazoan second messenger produced by DNA-
activated cyclic GMP-AMP synthase. Cell, 153:1094-1107.  
[5] Ablasser A, Goldeck M, Cavlar T, Deimling T, Witte G, Rohl I, et al. (2013). cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING. Nature, 498:380-384.  
[6] Tanaka Y, Chen ZJ (2012). STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal, 5:ra20.  
[7] Chen Q, Sun L, Chen ZJ (2016). Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing. Nature Immunology, 17:1142-1149.  
[8] Ablasser A, Chen ZJ (2019). cGAS in action: Expanding roles in immunity and inflammation. Science, 363: eaat8657.  
[9] Gao D, Li T, Li XD, Chen X, Li QZ, Wight-Carter M, et al. (2015). Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases. Proc Natl Acad Sci U S A, 112:E5699-5705.  
[10] Dou Z, Ghosh K, Vizioli MG, Zhu J, Sen P, Wangenstein KJ, et al. (2017). Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature, 550:402-406.  
[11] Woo SR, Fuertes MB, Corrales S, Spranger S, Furdyna MJ, Leung MY, et al. (2014). STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity, 41:830-842.  
[12] Xie W, Lama L, Adura C, Tomita D, Glickman JF, Tuschl T, et al. (2019). Human cGAS catalytic domain has an additional DNA-binding interface that enhances enzymatic activity and liquid-phase condensation. Proc Natl Acad Sci U S A, 116:11946-11955.  
[13] Luecke S, Holleufer A, Christensen MH, Jonsson KL, Boni GA, Sorensen LK, et al. (2017). cGAS is activated by DNA in a length-dependent manner. EMBO Rep, 18:1707-1715.  
[14] Riley JS, Quarato G, Cloix C, Lopez J, O’Prey J, Pearson M, et al. (2018). Mitochondrial inner membrane permeabilisation enables mtDNA release during apoptosis. EMBO J, 37:e99238.  
[15] McArthur K, Whitehead LW, Heddleston JM, Li L, Padman BS, Oorschot V, et al. (2018). BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis. Science, 359.  
[16] Rongvaux A, Jackson R, Harman CC, Li T, West AP, de Zoete MR, et al. (2014). Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA. Cell, 159:1563-1577.  
[17] White MJ, McArthur K, Metcalf D, Lane RM, Cambier JC, Herold MJ, et al. (2014). Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell, 159:1549-1562.  
[18] Hopfner KP, Hormung V (2020). Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat Rev Mol Cell Biol, 21:501-521.  
[19] Sun L, Wu J, Du F, Chen X, Chen ZJ (2013). Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science, 339:786-791.  
[20] Wolf C, Rapp A, Berndt N, Staroske W, Schuster M, Dobrick-Mattheuer M, et al. (2016). RPA and Rad51 constitute a cell intrinsic mechanism to protect the cytosol from self DNA. Nat Commun, 7:11752.  
[21] Volkman HE, Cambier S, Gray EE, Stetson DB (2019). Tight nuclear tethering of cGAS is essential for preventing autoreactivity. Elife, 8:e47941.  
[22] Gentili M, Lahaye X, Nadalin F, Nader GPF, Lombardi EP, Herve S, et al. (2019). The N-Terminal Domain of cGAS Determines Preferential Association with Centromeric DNA and Innate Immune Activation in the Nucleus. Cell Rep, 26:3798.  
[23] Michalski S, de Oliveira Mann CC, Stafford CA, Witte G, Bartho J, Lammens K, et al. (2020). Structural basis for sequestration and autoinhibition of cGAS by chromatin. Nature, 587:678-682.  
[24] Pathare GR, Decout A, Gluck S, Cavadini S, Makasheva K, Hovius R, et al. (2020). Structural mechanism of cGAS inhibition by the nucleosome. Nature, 587:668-672.  
[25] Zhao B, Xu P, Rowlett CM, Jing T, Shinde O, Lei Y, et al. (2020). The molecular basis of tight nuclear tethering and inactivation of cGAS. Nature, 587:673-677.  
[26] Kujirai T, Zierhut C, Takizawa Y, Kim R, Negishi L, Uruma N, et al. (2020). Structural basis for the inhibition of cGAS by nucleosomes. Science, 370:455-458.  
[27] Boyer J A, Spangler C J, Strauss J D, Cesmat A P, Liu P, McGinty R K, et al. (2020). Structural basis of nucleosome-dependent cGAS inhibition. Science, 370:450-454.  
[28] Barnett KC, Coronas-Serna JM, Zhou W, Ernandes MJ, Cao A, Kranzusch PJ, et al. (2019). Phosphoinositide Interactions Position cGAS at the Plasma Membrane to Ensure Efficient Distinction between Self- and Viral DNA. Cell, 176:1432-1446 e11.  
[29] Diner EJ, Burdette DL, Wilson SC, Monroe KM, Kellenberger CA, Hyodo M, et al. (2013). The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell Rep, 3:1355-1361.  
[30] Burdette DL, Monroe KM, Sotelo-Troha K, Iwig JS, Eckert B, Hyodo M, et al. (2011). STING is a direct innate immune sensor of cyclic di-GMP. Nature, 478:515-518.  
[31] Barker JR, Koestler BJ, Carpenter VK, Burdette DL, Waters CM, Vance RE, et al. (2013). STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection. mBio, 4:e00018-00013.  
[32] Abe T, Harashima A, Xia T, Konno H, Konno K, Morales A, et al. (2013). STING recognition of cytoplasmic DNA instigates cellular defense. Mol Cell, 50:5-15.  
[33] Ablasser A, Schmid-Burgk JL, Hemmerling I, Horvath GL, Schmidt T, Latz E, et al. (2013). Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature, 503:530-534.
[34] Bridgeman A, Maelfait J, Davenne T, Partridge T, Peng Y, Mayer A, et al. (2015). Viruses transfer the antiviral second messenger cGAMP between cells. Science, 349:1228-1232.

[35] Luteijn RD, Zaver SA, Gowen BG, Wyman SK, Garelis NE, Onia L, et al. (2019). SLC19A1 transports immunoreactive cyclic dinucleotides. Nature, 573:434-438.

[36] Ritchie C, Cordova AF, Hess GT, Bassik MC, Li L (2019). SLC19A1 Is an Importer of the Immunotransmitter cGAMP. Mol Cell, 75:372-381 e5.

[37] Zhou C, Chen X, Planells-Cases R, Chu J, Wang L, Cao L, et al. (2020). Transfer of cGAMP into Bystander Cells via LRRC8 Volume-Regulated Anion Channels Augments STING-Mediated Interferon Responses and Anti-viral Immunity. Immunity, 52:767-781 e6.

[38] Lahey LJ, Mardjuki RE, Wen X, Hess GT, Ritchie C, Carozza JA, et al. (2020). LRRRC8A/C/E Heteromeric Channels Are Ubiquitous Transporters of cGAMP. Mol Cell, 80:578-591 e5.

[39] Li L, Yin Q, Kuss P, Maliga Z, Millan JL, Wu H, et al. (2014). Hydrolysis of 2′,3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs. Nat Chem Biol, 10:1043-1048.

[40] Liu H, Moura-Alves P, Pei G, Mollenkopf HJ, Hurwitz R, Wu X, et al. (2019). cGAS facilitates sensing of extracellular cyclic dinucleotides to activate innate immunity. EMBO Rep, 20:e46293.

[41] Srikanth S, Woo JS, Wu B, El-Sherbiny YM, Leung J, Chupradit K, et al. (2019). The Ca2+ sensor STIM1 regulates the type I interferon response by retaining the signaling adaptor STING at the endoplasmic reticulum. Nature Immunology, 20:152-162.

[42] Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang S-Y, et al. (2018). Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature, 564:439-444.

[43] Dobbs N, Burnaevskiy N, Chen D, Gonugunta VK, Alto NM, Yan N (2015). STING Activation by Translocation from the ER Is Associated with Infection and Autoinflammatory Disease. Cell Host Microbe, 18:157-168.

[44] Zhang BC, Nandakumar R, Reinert LS, Huang J, Laautsen A, Gao ZL, et al. (2020). STEEP mediates STING ER exit and activation of signaling. Nat Immunol, 21:868-879.

[45] Wei J, Lian H, Guo W, Chen YD, Zhang XN, Zang R, et al. (2018). SNX8 modulates innate immune response to DNA virus by mediating trafficking and activation of MTA. PLoS Pathog, 14:e1007336.

[46] Luo W-W, Li S, Li C, Lian H, Yang Q, Zhong B, et al. (2016). iRho2 is essential for innate immunity to DNA viruses by mediating trafficking and stability of the adaptor STING. Nature Immunology, 17:1057-1066.

[47] Feng P, Chen W, Li S, Yu H, Liu X, Huang L, et al. (2016). ER Adaptor SCAP Translocates and Recruits IRF3 to Perinuclear Microsome Induced by Cytosolic Microbial DNAs. PLOS Pathogens, 12:e1005462.

[48] Wang Q, Liu X, Cui Y, Tang Y, Chen W, Li S, et al. (2014). The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. Immunity, 41:919-933.

[49] Sun MS, Zhang J, Jiang LQ, Pan YX, Tan JY, Yu F, et al. (2018). TMED2 Potentiates Cellular IFN Responses to DNA Viruses by Reinforcing MITA Dimerization and Facilitating Its Trafficking. Cell Rep, 25:3086-3098 e3.

[50] Ishikawa H, Ma Z, Barber GN (2009). STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature, 461:788-792.

[51] Konno H, Konno K, Barber Glen N (2013). Cyclic Dinucleotides Trigger ULK1 (ATG1) Phosphorylation of STING to Prevent Sustained Innate Immune Signaling. Cell, 155:688-698.

[52] Ogawa E, Mukai K, Saito K, Arai H, Taguchi T (2018). The binding of TBK1 to STING requires exocytic membrane traffic from the ER. Biochem Biophys Res Commun, 503:138-145.

[53] Volpi S, Tsui J, Mariani M, Pastorino C, Caorsi R, Sacco O, et al. (2018). Type I interferon pathway activation in COPA syndrome. Clinical Immunology, 187:33-36.

[54] Lepelley A, Martin-Nicolos MJ, Le Bihan M, Marsh JA, Uggetti C, Rice GI, et al. (2020). Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling. J Exp Med, 217:e20200600.

[55] Mukai K, Konno H, Akiba T, Uemura T, Waguri S, Kobayashi T, et al. (2016). Activation of STING requires palmitoylation at the Golgi. Nat Commun, 7:11932.

[56] Hansen AL, Mukai K, Schopfer FJ, Taguchi T, Holm CK (2019). STING palmitoylation as a therapeutic target. Cell Mol Immunol, 16:236-241.

[57] Chen Q, Sun L, Chen ZJ (2016). Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol, 17:1142-1149.

[58] Song ZM, Lin H, Yi XM, Guo W, Hu MM, Shu HB (2020). KAT5 acetylates cGAS to promote innate immune response to DNA virus. Proc Natl Acad Sci U S A, 117:21568-21575.

[59] Wang Q, Huang L, Hong Z, Lv Z, Mao Z, Tang Y, et al. (2017). The E3 ubiquitin ligase RNF185 facilitates the cGAS-mediated innate immune response. PLoS Pathog, 13:e1006264.

[60] Seo GJ, Kim C, Shin W-J, Sklan EH, Eoh H, Jung JU (2018). TRIM56-mediated monoubiquitination of cGAS for cytosolic DNA sensing. Nature Communications, 9:613.

[61] Chen M, Meng Q, Qin Y, Liang P, Tan P, He L, et al. (2016). TRIM14 Inhibits cGAS Degradation Mediated by Selective Autophagy Receptor p62 to Promote Innate Immune Responses. Mol Cell, 64:105-119.

[62] Seo GJ, Yang A, Tan B, Kim S, Liang Q, Choi Y, et al. (2015). Akt Kinase-Mediated Checkpoint of cGAS DNA Sensing Pathway. Cell Rep, 13:440-449.

[63] Hu MM, Yang Q, Xie XQ, Liao CY, Lin H, Liu TT, et al. (2016). Sumoylation Promotes the Stability of the
DNA Sensor cGAS and the Adaptor STING to Regulate the Kinetics of Response to DNA Virus. Immunity, 45:555-569.

[64] Cui Y, Yu H, Zheng X, Peng R, Wang Q, Zhou Y, et al. (2017). SENP7 Potentiates cGAS Activation by Relieving SUMO-Mediated Inhibition of Cytosolic DNA Sensing. PLoS Pathog, 13:e1006156.

[65] Xia P, Ye B, Wang S, Zhu X, Du Y, Xiong Z, et al. (2016). Glutamylation of the DNA sensor cGAS regulates its binding and synthase activity in antiviral immunity. Nat Immunol, 17:369-378.

[66] Liu ZS, Cai H, Xue W, Wang M, Xia T, Li WJ, et al. (2019). G3BP1 promotes DNA binding and activation of cGAS. Nat Immunol, 20:18-28.

[67] Ghosh A, Shao L, Sampath P, Zhao B, Patel NV, Zhu J, et al. (2019). Oligoadenylate-Synthetase-Family Protein OASL Inhibits Activity of the DNA Sensor cGAS during DNA Virus Infection to Limit Interferon Production. Immunity, 50:51-63 e5.

[68] Lian H, Wei J, Zang R, Ye W, Yang Q, Zhang X-N, et al. (2018). ZCCHC3 is a co-sensor of cGAS for dsDNA recognition in innate immune response. Nature Communications, 9:3349.

[69] Tsuchida T, Zou J, Saitoh T, Kumar H, Abe T, Matsuura Y, et al. (2010). The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. Immunity, 33:765-776.

[70] Zhang J, Hu MM, Wang YY, Shu HB (2012). TRIM32 protein modulates type I interferon induction and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. J Biol Chem, 287:28646-28655.

[71] Ni G, Konno H, Barber GN (2017). Ubiquitination of STING at lysine 224 controls IRF3 activation. Sci. Immunol, 2:aah7119.

[72] Wang Y, Lian Q, Yang B, Yan S, Zhou H, He L, et al. (2015). TRIM30alpha Is a Negative-Feedback Regulator of the Intracellular DNA and DNA Virus-Triggered Response by Targeting STING. PLoS Pathog, 11:e1005012.

[73] Zhong B, Zhang L, Lei C, Li Y, Mao AP, Yang Y, et al. (2009). The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA. Immunity, 30:397-407.

[74] Xing J, Zhang A, Zhang H, Wang J, Li XC, Zeng MS, et al. (2017). TRIM29 promotes DNA virus infections by inhibiting innate immune response. Nat Commun, 8:945.

[75] Qin Y, Zhou MT, Hu MM, Hu YH, Zhang J, Guo L, et al. (2014). RNF26 temporarily regulates virus-triggered type I interferon induction by two distinct mechanisms. PLoS Pathog, 10:e1004358.

[76] Tian M, Liu W, Zhang Q, Huang Y, Li W, Wang W, et al. (2020). MYSM1 Represses Innate Immunity and Autoimmunity through Suppressing the cGAS-STING Pathway. Cell Rep, 33:108297.

[77] Ye L, Zhang Q, Liuyu T, Xu Z, Zhang MX, Luo MH, et al. (2019). USP49 negatively regulates cellular antiviral responses via deconjugating K63-linked ubiquitination of MITA. PLoS Pathog, 15:e1007680.

[78] Zhang MX, Cai Z, Zhang M, Wang XM, Wang Y, Zhao F, et al. (2019). USP20 Promotes Cellular Antiviral Responses via Deconjugating K48-Linked Ubiquitination of MITA. J Immunol, 202:2397-2406.

[79] Zhang L, Wei N, Cui Y, Hong Z, Liu X, Wang Q, et al. (2018). The deubiquitinase CYLD is a specific checkpoint of the STING antiviral signaling pathway. PLoS Pathog, 14:e1007435.

[80] Chen Y, Wang L, Jin J, Luan Y, Chen C, Li Y, et al. (2017). p38 inhibition provides anti–DNA virus immunity by regulation of USP21 phosphorylation and STING activation. Journal of Experimental Medicine, 214:991-1010.

[81] Sun H, Zhang Q, Jing YY, Zhang M, Wang HY, Cai Z, et al. (2017). USP13 negatively regulates antiviral responses by deubiquitinating STING. Nat Commun, 8:15534.

[82] Xia T, Yi X-M, Wu X, Shang J, Shu H-B (2019). PTNP1/2-mediated dephosphorylation of MITA/STING promotes its 20S proteasomal degradation and attenuates innate antiviral response. Proceedings of the National Academy of Sciences, 116:20063-20069.

[83] Li Z, Liu G, Sun L, Teng Y, Guo X, Jia J, et al. (2015). PPM1A regulates antiviral signaling by antagonizing TBK1-mediated STING phosphorylation and aggregation. PLoS Pathog, 11:e1004783.

[84] Wang F, Alain T, Szeretter KJ, Stephenson K, Pol JG, Atherton MJ, et al. (2016). S6K-STING interaction regulates cytotoxic DNA-mediated activation of the transcription factor IRF3. Nat Immunol, 17:514-522.

[85] Pokatayev V, Yang K, Tu X, Dobbs N, Wu J, Kalb RG, et al. (2020). Homeostatic regulation of STING protein at the resting state by stabilizer TOLLIP. Nature Immunology, 21:158-167.

[86] Zhang L, Mo J, Swanson KV, Wen H, Petrucchini A, Gregory SM, et al. (2014). NLRX1, a member of the NLR family of proteins, is a negative regulator of innate immune signaling induced by the DNA sensor STING. Immunity, 40:329-341.

[87] Guo H, Ko R, Deng M, Duncan J, A., Chanda S, K., Ting J, P.-Y. (2016). NLRX1 Sequesters STING to Negatively Regulate the Interferon Response, Thereby Facilitating the Replication of HIV-1 and DNA Viruses. Cell Host Microbe, 19:515-528.

[88] Barouch DH, Ghneim K, Bosche WJ, Li Y, Berkemeier B, Hull M, et al. (2016). Rapid Inflammasome Activation following Mucosal SIV Infection of Rhesus Monkeys. Cell, 165:656-667.

[89] Zhou Q, Lin H, Wang S, Wang S, Ran Y, Liu Y, et al. (2014). The ER-Associated Protein ZDHHC1 Is a Positive Regulator of DNA Virus-Triggered, MITA/STING-Dependent Innate Immune Signaling. Cell Host & Microbe, 16:450-461.

[90] Li Y, James SJ, Wylie DH, Wynne C, Czibula A, Bhak J, et al. (2019). TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages. Proc Natl Acad Sci U S A, 116:16479-16488.
[91] Leng F, Edison P (2020). Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol.

[92] Simon DW, McGeachy MJ, Bayir H, Clark RS, Loane DJ, Kochanek PM (2017). The far-reaching scope of neuroinflammation after traumatic brain injury. Nat Rev Neurol, 13:171-191.

[93] Shen F, Jiang L, Han F, Degos V, Chen S, Su H (2019). Increased Inflammatory Response in Old Mice is Associated with More Severe Neuronal Injury at the Acute Stage of Ischemic Stroke. Aging Dis, 10:12-22.

[94] Russo MV, McGavern DB (2015). Immune Surveillance of the CNS following Infection and Injury. Trends Immunol, 36:637-650.

[95] DiSabato DJ, Quan N, Godbout JP (2016). Neuroinflammation: the devil is in the details. J Neurochem, 139 Suppl 2:136-153.

[96] Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, et al. (2015). Neuroinflammation in Alzheimer's disease. The Lancet Neurology, 14:388-405.

[97] Wang L, Liu Y, Yan S, Du T, Fu X, Gong X, et al. (2020). Disease Progression-Dependent Expression of CD200R1 and CX3CR1 in Mouse Models of Parkinson's Disease. Aging Dis, 11:254-268.

[98] Li Q, Cao Y, Dang C, Han B, Han R, Ma H, et al. (2020). Inhibition of double-strand DNA-sensing cGAS ameliorates brain injury after ischemic stroke. EMBO Mol Med, 12:e11002.

[99] Liao Y, Cheng J, Kong X, Li S, Li X, Zhang M, et al. (2020). HDAC3 inhibition ameliorates ischemia/reperfusion-induced brain injury by regulating the microglial cGAS-STING pathway. Theranostics, 10:9644-9662.

[100] Lv J, Li S, Zhang J, Duan F, Wu Z, Chen R, et al. (2020). In vivo photoacoustic imaging dynamically monitors the structural and functional changes of ischemic stroke at a very early stage. Theranostics, 10:816-828.

[101] McDonough A, Lee RV, Noor S, Lee C, Le T, Iorga M, et al. (2017). Ischemia/Reperfusion Induces Interferon-Stimulated Gene Expression in Microglia. J Neurosci, 37:8292-8308.

[102] Zhang M, Downes CE, Wong CHY, Brody KM, Guio-Agualair PL, Gould J, et al. (2017). Type-I interferon signalling through IFNAR1 plays a deleterious role in the outcome after stroke. Neurochem Int, 108:47-58.

[103] Li L, Qin JJ, Guo S, Zhang P, Gong J, Zhang XJ, et al. (2016). Attenuation of cerebral ischemic injury in interferon regulatory factor 3-deficient rat. J Neurochem, 136:871-883.

[104] Kang L, Yu H, Yang X, Zhu Y, Bai X, Wang R, et al. (2020). Neutrophil extracellular traps released by neutrophils impair revascularization and vascular remodeling after stroke. Nat Commun, 11:2488.

[105] Khey KMW, Huard A, Mahmoud SH (2020). Inflammatory Pathways Following Subarachnoid Hemorrhage. Cell Mol Neurobiol, 40:675-693.

[106] Xu W, Li T, Gao L, Zheng J, Yan J, Zhang J, et al. (2019). Apelin-13/APJ system attenuates early brain injury via suppression of endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation and oxidative stress in a AMPK-dependent manner after subarachnoid hemorrhage in rats. J Neuroinflammation, 16:247.

[107] Xu H, Li J, Wang Z, Feng M, Shen Y, Cao S, et al. (2017). Methylene blue attenuates neuroinflammation after subarachnoid hemorrhage in rats through the Akt/GSK-3beta/MEF2D signaling pathway. Brain Behav Immun, 65:125-139.

[108] Peng Y, Zhuang J, Ying G, Zeng H, Zhou H, Cao Y, et al. (2020). Stimulator of IFN genes mediates neuroinflammatory injury by suppressing AMPK signal in experimental subarachnoid hemorrhage. J Neuroinflammation, 17:165.

[109] Chin AC (2020). PERK-STING Signaling Drives Neuroinflammation in Traumatic Brain Injury. J Neurosci, 40:2384-2386.

[110] Piscitutti F, Micotti E, Hay JR, Marongiu I, Sannami E, Tolomeo D, et al. (2018). Single severe traumatic brain injury produces progressive pathology with ongoing contralateral white matter damage one year after injury. Exp Neurol, 300:167-178.

[111] Corps KN, Roth TL, McGavern DB (2015). Inflammation and neuroprotection in traumatic brain injury. JAMA Neurol, 72:355-362.

[112] Karve JP, Zhang M, Habgood M, Frugier T, Brody KM, Sashidranath M, et al. (2016). Ablation of Type-I IFN Signaling in Hematopoietic Cells Confers Protection Following Traumatic Brain Injury. eNeuro, 3:ENEURO.0128-15.2016.

[113] Barrett JP, Henry RJ, Shirey KA, Doran SJ, Makarevich OD, Ritzel RM, et al. (2020). Interferon-β Plays a Detrimental Role in Experimental Traumatic Brain Injury by Enhancing Neuroinflammation That Drives Chronic Neurodegeneration. The Journal of Neuroscience, 40:2357-2370.

[114] Abdullah A, Zhang M, Frugier T, Bedoui S, Taylor JM, Crack PJ (2018). STING-mediated type-I interferons contribute to the neuroinflammatory process and detrimental effects following traumatic brain injury. Journal of Neuroinflammation, 15:323.

[115] Sen T, Saha P, Gupta R, Foley LM, Jiang T, Abakumova OS, et al. (2020). Aberrant ER Stress Induced Neuronal-IFNbeta Elicits White Matter Injury Due to Microglial Activation and T-Cell Infiltration after TBI. J Neurosci, 40:424-446.

[116] Sen T, Gupta R, Kaiser H, Sen N (2017). Activation of PERK Elicits Memory Impairment through Inactivation of CREB and Downregulation of PSD95 After Traumatic Brain Injury. J Neurosci, 37:5900-5911.

[117] Liu Y, Zhan J-K, Zhao Y (2020). A Perspective on Roles Played by Immunosenescence in the Pathobiology of Alzheimer's Disease. Aging and disease, 11:1594-1607.

[118] Poon CH, Wang Y, Fung ML, Zhang C, Lim LW (2020). Rodent Models of Amyloid-Beta Feature of Alzheimer’s Disease: Development and Potential Treatment Implications. Aging Dis, 11:1235-1259.
Guo X, Liu Y, Morgan D, Zhao LR (2020). Reparative Effects of Stem Cell Factor and Granulocyte Colony-Stimulating Factor in Aged APP/PS1 Mice. Aging Dis, 11:1423-1443.

Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, et al. (2013). Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell, 153:707-720.

Hanzel CE, Pichet-Binette A, Pimentel LS, Iulita MF, Allard S, Ducatenzeiler A, et al. (2014). Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol Aging, 35:2249-2262.

Femminella GD, Dani M, Wood M, Fan Z, Calsolaro V, Atkinson R, et al. (2019). Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. Neurology, 92:e1331-e1343.

Passamonti L, Tsvetanov KA, Jones PS, Bevan-Jones WR, Arnold R, Borchert RJ, et al. (2019). Neuroinflammation and Functional Connectivity in Alzheimer's Disease: Interactive Influences on Cognitive Performance. J Neurosci, 39:7218-7226.

Martin E, Boucher C, Fontaine B, Delarasse C (2017). Distinct inflammatory phenotypes of microglia and monocyte-derived macrophages in Alzheimer's disease models: effects of aging and amyloid pathology. Aging Cell, 16:27-38.

Lan YY, Heather JM, Eisenhaure T, Garris CS, Lieb D, Raychowdhury R, et al. (2019). Extraneural DNA accumulates in aged cells and contributes to senescence and inflammation. Aging Cell, 18:e12901.

Vizioli MG, Liu T, Miller KN, Robertson NA, Gilroy K, Lagnado AB, et al. (2020). Mitochondria-to-nucleus retrograde signaling drives formation of cytoplasmic chromatin and inflammation in senescence. Genes Dev, 34:428-445.

Guerreiro R, Wojtas A, Bras J, Carraquillo M, Rogaea E, Majounie E, et al. (2013). TREM2 variants in Alzheimer's disease. N Engl J Med, 368:117-127.

Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. (2013). Variant of TREM2 Associated with the Risk of Alzheimer's Disease. New England Journal of Medicine, 368:107-116.

Wang Y, Cellar M, Mallinson K, Ulrich JD, Young KL, Robinette ML, et al. (2015). TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell, 160:1061-1071.

Xu Q, Xu W, Cheng H, Yuan H, Tan X (2019). Efficacy and mechanism of cGAMP to suppress Alzheimer's disease by elevating TREM2. Brain Behav Immun, 81:495-508.

Song X, Ma F, Herrup K (2019). Accumulation of Cytoplasmic DNA Due to ATM Deficiency Activates the Microglial Viral Response System with Neurotoxic Consequences. J Neurosci, 39:6378-6394.

Hartlova A, Erttmann SF, Raffi FA, Schmalz AM, Resch U, Anugula S, et al. (2015). DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity, 42:332-343.

Hu M, Zhou M, Bao X, Pan D, Jiao M, Liu X, et al. (2020). ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage/cGAS-STING activation. J Clin Invest.

Quek H, Luff J, Cheung K, Kozlov S, Gatei M, Lee CS, et al. (2017). A rat model of ataxia-telangiectasia: evidence for a neurodegenerative phenotype. Hum Mol Genet, 26:109-123.

Quek H, Luff J, Cheung K, Kozlov S, Gatei M, Lee CS, et al. (2017). Rats with a missense mutation in Atm display neuroinflammation and neurodegeneration subsequent to accumulation of cytosolic DNA following unrepaired DNA damage. J Leukoc Biol, 101:927-947.

Gronek P, Haas AN, Czarny W, Podstawski R, Delabary MDS, Clark CC, et al. (2021). The Mechanism of Physical Activity-induced Amelioration of Parkinson's Disease: A Narrative Review. Aging Dis, 12:192-202.

Weindel CG, Bell SL, Vail KJ, West KO, Patrick KL, Watson RO (2020). LRRK2 maintains mitochondrial homeostasis and regulates innate immune responses to Mycobacterium tuberculosis. eLife, 9:e51071.

Pickrell AM, Youle RJ (2015). The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron, 85:257-273.

Pickrell AM, Huang CH, Kennedy SR, Ordureau A, Sideris DP, Hoekstra JG, et al. (2015). Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress. Neuron, 87:371-381.

Sliter DA, Martinez J, Hao L, Chen X, Sun N, Fischer TD, et al. (2018). Parkin and PINK1 mitigate STING-induced inflammation. Nature, 561:258-262.

Lee JJ, Andreazza S, Whittworth AJ (2020). The STING pathway does not contribute to behavioural or mitochondrial phenotypes in Drosophila PINK1/parkin or mtDNA mutator models. Sci Rep, 10:2693.

Borsche M, Konig IR, Delcambre S, Petrucci S, Balck A, Bruggemann N, et al. (2020). Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism. Brain, 143:3041-3051.

Li HL, Li XY, Dong Y, Zhang YB, Cheng HR, Gan SR, et al. (2019). Clinical and Genetic Profiles in Chinese Patients with Huntington's Disease: A Ten-year Multicenter Study in China. Aging Dis, 10:1003-1011.

Crotti A, Glass CK (2015). The choreography of neuroinflammation in Huntington's disease. Trends Immunol, 36:364-373.

von Essen MR, Hellem MNN, Vinther-Jensen T, Ammitzbol C, Hansen RH, Hjermand LE, et al. (2020). Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease. Ann Neurol, 87:246-255.

Sharma M, Rajendrarao S, Shahani N, Ramirez-Jarquin UN, Subramaniam S (2020). Cyclic GMP-AMP synthase promotes the inflammatory and autophagy responses in Huntington disease. Proc Natl Acad Sci U S A, 117:15989-15999.

Li F., et al. cGAS-STING in CNS Disorders

Aging and Disease • Volume 12, Number 7, October 2021
Activation of the STING pathway in microglia orchestrates antiviral defence in the CNS. Nat Immunol. 16:231.

Bodda C, Reinert LS, Fruhwurth S, Richardo T, Sun C, Petras G, Esser EH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am. J. Med. Genet, 167A:296-312.

Hasan M, Dobbs N, Khan S, White MA, Wakeland EK, Li QZ, et al. (2015). Cutting Edge: Inhibiting TBK1 by Compound II Ameliorates Autoimmune Disease in Mice. J Immunol, 195:4573-4577.

Pokatayev V, Hasin N, Chon H, Cerritelli SM, Sakhuja K, Ward JM, et al. (2016). RNase H2 catalytic core Aicardi-Goutieres syndrome-related mutant invokes cGAS-STING innate immune-sensing pathway in mice. J Exp Med, 213:329-336.

Coquel F, Silva MJ, Techer H, Zadorozhny K, Sharma S, Niemiuszczey J, et al. (2018). SAMHD1 acts at stalled replication forks to prevent interferon induction. Nature, 557:57-61.

Tyler KL, Ropper AH (2018). Acute Viral Encephalitis. New England Journal of Medicine, 379:557-566.

Reintert LS, Lopusus K, Winther H, Sun C, Thomsen MK, Nandakumar R, et al. (2016). Sensing of HSV-1 by the cGAS-STING pathway in microglia orchestrates antiviral defence in the CNS. Nat Commun, 7:13348.

Reintert LS, Rashidi AS, Tran DN, Katzileris-Petras G, Hvidt AK, Gohr M, et al. (2020). Brain immune cells undergo cGAS-STING-dependent apoptosis during herpes simplex virus type 1 infection. J Clin Invest, 131:e136824.

Bodda C, Reinert LS, Fruhwurth S, Richardo T, Sun C, Zhang BC, et al. (2020). HSV1 VP1-2 deubiquitinates STING to block type I interferon expression and promote brain inflammation. J Exp Med, 217:e20191422.

Zhao J, Zhao J, Xu S, Li J, He S, Zeng Y, et al. (2018). Species-Specific Deamidation of cGAS by Herpes Simplex Virus UL37 Protein Facilitates Viral Replication. Cell Host Microbe, 24:234-248 e5.

Nazmi A, Mukhopadhyay R, Dutta K, Basu A (2012). STING mediates neuronal innate immune response following Japanese encephalitis virus infection. Sci Rep, 2:347.

McGuckin Wuerzt K, Treuting PM, Hemann EA, Esser-Nobis K, Snyder AG, Graham JB, et al. (2019). STING is required for host defense against...
neuropathological West Nile virus infection. PLoS Pathog, 15:e1007899.

[176] Rubin EJ, Greene MF, Baden LR (2016). Zika Virus and Microcephaly. N Engl J Med, 374:984-985.

[177] Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y, et al. (2016). Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth. Cell Stem Cell, 18:587-590.

[178] Liu Y, Gordesky-Gold B, Leney-Greene M, Weinbren NL, Tudor M, Cherry S (2018). Inflammation-Induced, STING-Dependent Autophagy Restricts Zika Virus Infection in the Drosophila Brain. Cell Host & Microbe, 24:57-68.e3.

[179] Cao B, Parnell LA, Diamond MS, Mysorekar IU (2017). Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice. J Exp Med, 214:2303-2313.

[180] Ding Q, Gaska JM, Douam F, Wei L, Kim D, Balev M, et al. (2018). Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease. Proc Natl Acad Sci U S A, 115:E6310-E6318.

[181] Lennemann NJ, Coyne CB (2017). Dengue and Zika viruses subvert reticulophagy by NS2B3-mediated cleavage of FAM134B. Autophagy, 13:322-332.